Effects of Repeated Psilocybin Dosing in OCD

• Status: Not yet recruiting
• Trial end date: 2026-11-01
• Target enrollment: 0
• Participant gender: All

Summary

This study aims to investigate the effects of repeated dosing of oral psilocybin on obsessive-compulsive disorder (OCD) symptomatology in a randomized, waitlist-controlled design with blinded independent ratings, and assess psychological mechanisms that may mediate psilocybin's therapeutic effects on OCD.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Yale University
• Collaborator: Steven & Alexandra Cohen Foundation
• Treatments: Psilocybin

Criteria

Inclusion Criteria:

1. Primary DSM-5 diagnosis of OCD

2. Patients must have failed at least one medication and/or therapy trial of standard care treatment for OCD

3. English fluency

4. Agree to refrain from taking or starting any psychiatric medications during the study period.

5. Agree to pause current or not initiate new course of psychotherapy for OCD during the study period.

6. If participant is a female of childbearing potential, must have a negative pregnancy test at study entry and prior to each dosing session.

7. Must agree to use adequate birth control throughout study duration.

Exclusion Criteria:

1. Unremitted Tourette syndrome

2. Pregnant or lactating women

3. Unable or unwilling to adhere to contraceptive measures

4. Positive urine drug test for any prohibited substance, or positive breathalyzer test for alcohol, at screening or day of dosing

5. Any unstable medical condition that my render study procedures unsafe